Arbutus Terminated Phase 2a Clinical Trial Evaluating Safety, Tolerability and Antiviral Activity of Imdusiran and NA Therapy in Combo With Intermittent Low Doses of Durvalumab >ABUS
Arbutus Terminated Phase 2a Clinical Trial Evaluating Safety, Tolerability and Antiviral Activity of Imdusiran and NA Therapy in Combo With Intermittent Low Doses of Durvalumab >ABUS
Arbutus中止了IIa期临床试验，该试验评估了Imdusiran和NA疗法与间歇性低剂量Durvalumab联合使用的安全性、耐受性和抗病毒活性>ABUS
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册